The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pancancer survival analysis of cancer hallmark genes
Open accessAbstract
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G. M., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M. A. M., Gelder, M. E. M., Yu, J. X., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,831
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Cited by
Sorted by citations
Items 501–600 of 1,000
Xu, H., Bai, J., Tian, Y., Feng, X., Chen, A., Wang, J., Wu, J., Jin, X., Zhang, F., Quan, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.5397 · Cited by 7
The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 InfectionPreprint
McDonald, J., Enguita, F. J., Taylor, D. M., Griffin, R. J., Priebe, W., Emmett, M. R., Sajadi, M. M., Harris, A. D., Clement, J., Dybas, J. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.23.441024 · Cited by 7
A large-scale foundation model for bulk transcriptomesPreprint
Kang, B., Fan, R., Yi, M., Cui, C., & Cui, Q. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.659222 · Cited by 7
Implications of MTHFD2 expression in renal cell carcinoma aggressiveness
SILVA, R. V. N., Berzotti, L. A., Laia, M. G. D., Araújo, L. S., da Silva, C. A., Ribeiro, K. B., Brandão, M., Michelleti, A. M. R., Machado, J. R., & Lira, R. C. P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299353 · Cited by 7
Garcia‐Vicién, G., Ruíz, N., Micke, P., Ruffinelli, J. C., Mils, K., Bañuls, M., Molina, N. M., Pardo, M. A., Lladó, L., Mezheyeuski, A., et al. (2024) · MedComm · doi:10.1002/mco2.70000 · Cited by 7
Zhou, H., Gong, H., Zeng, X., Zeng, C., Liu, D., Liu, J., & Zhang, Y. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5509 · Cited by 6
Proteomic insights into lymph node metastasis in breast cancer subtypes: Key biomarkers and pathways
Albayrak, M. G. B., Şimşek, T., Akpınar, G., Kasap, M., & Cantürk, N. Z. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155938 · Cited by 6
Role of the SPI1/CDKN2A/p53 signaling pathway in cuproptosis of lung adenocarcinoma cells
An, J., Song, W., Wang, Q., Tan, B., Fei, X., Wang, R., Li, S., Lu, X., Li, Y., & Xie, N. (2025) · Oncology Letters · doi:10.3892/ol.2025.15099 · Cited by 6
Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives
Yücer, R., Piccinno, R., Ooko, E., Dawood, M., Bringmann, G., & Efferth, T. (2025) · Biomolecules · doi:10.3390/biom15070971 · Cited by 6
BulkFormer: A large-scale foundation model for bulk transcriptomes
Kang, B. S., Fan, R., Yi, M., Cui, C., & Cui, Q. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101657 · Cited by 17
Makki, A. A., Ibraheem, W., & Alzain, A. A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2167122 · Cited by 6
Zheng, A., Bai, J., Ha, Y., Yu, Y., Fan, Y., Liang, M., Lu, Y., Shen, Z., Luo, B., & Jie, W. (2023) · BMC Cancer · doi:10.1186/s12885-023-10616-9 · Cited by 6
Yang, S., Luo, Y., Zhou, D., Xiang, J., & Xi, X. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-742 · Cited by 6
Zhou, Y., Zhang, X., Gao, Y., Peng, Y., Liu, P., Chen, Y., Guo, C., Deng, G., Ouyang, Y., Zhang, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110318 · Cited by 6
Dar, O. A., Hashmi, A. A., Al‐Bogami, A. S., Ahmad, A., & Wani, M. Y. (2024) · Dalton Transactions · doi:10.1039/d4dt01209g · Cited by 6
Wen, B., Chen, J., Ding, T., Mao, Z., Jin, R., Wang, Y., Shi, M., Zhao, L., Yang, A., Qin, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-69638-3 · Cited by 8
SAMD1 suppresses epithelial–mesenchymal transition pathways in pancreatic ductal adenocarcinoma
Simon, C., Brunke, I. D., Stielow, B., Forné, I., Steitz, A. M., Geller, M., Rohner, I., Weber, L. M., Fischer, S., Jeude, L. M., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002739 · Cited by 6
Zhang, S., Cao, G., Shen, S., Wu, Y. C., Tan, X., & Jiang, X. (2024) · PeerJ · doi:10.7717/peerj.18428 · Cited by 6
D’Souza, D. P., Bik, L., Giwa, O. D., Cohen, S., Barazany, H. L., Siegal, T., & Frenkel‐Morgenstern, M. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1126 · Cited by 6
Decreased prostasin expression is associated with aggressiveness of oral squamous cell carcinoma
Yamamoto, K., Yamashita, F., Kawaguchi, M., Izumi, A., Kiwaki, T., Kataoka, H., Kaneuji, T., Yamashita, Y., & Fukushima, T. (2021) · Human Cell · doi:10.1007/s13577-021-00575-3 · Cited by 6
Napolitano, V., Russo, D., Morra, F., Merolla, F., Varricchio, S., Ilardi, G., Crescenzo, R. M. D., Martino, F., Mascolo, M., Celetti, A., et al. (2021) · Cancers · doi:10.3390/cancers13153822 · Cited by 6
Xu, F., Tian, D., Shi, X., Sun, K., & Chen, Y. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609914 · Cited by 6
High ORAI3 expression correlates with good prognosis in human muscle-invasive bladder cancer
Yan, J., Yu, W., Lu, C., Liu, C., Wang, G., Jiang, L., Jiang, Z., & Qin, Z. (2021) · Gene · doi:10.1016/j.gene.2021.145994 · Cited by 6
MicroRNA‑337‑3p impedes breast cancer progression by targeting cyclin‑dependent kinase 1
Kong, S., Liu, J., Zhang, B., Lv, F., Yu, Y., & Qin, T. (2021) · Oncology Letters · doi:10.3892/ol.2021.13133 · Cited by 6
Nuclear Factor IA Is Down-regulated in Muscle-invasive and High-grade Bladder Cancers
Kaczorowski, M., MATYSIAK, J., Kiełb, P., Małkiewicz, B., & Hałoń, A. (2021) · Anticancer Research · doi:10.21873/anticanres.15507 · Cited by 6
Petronek, M. S., Tomanek‐Chalkley, A., Monga, V., Milhem, M. M., Miller, B. J., Magnotta, V. A., & Allen, B. G. (2022) · PubMed Central · Cited by 6
Madgwick, S., Luli, S., Sellier, H., Butterworth, J. A., Leslie, J., Moore, A. J., Corbin, E. K., Yemm, A. I., Chiremba, R. T., TINIAKOS, D. G., et al. (2022) · Biochemical Journal · doi:10.1042/bcj20220101 · Cited by 6
Chicco, D., Alameer, A., Rahmati, S., & Jurman, G. (2022) · BioData Mining · doi:10.1186/s13040-022-00312-y · Cited by 6
Immunological role and prognostic value of SPARCL1 in pan-cancer analysis
He, K., Li, C., Yuan, H., Jiang, K., & Deng, G. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610687 · Cited by 6
A Pan-Cancer Atlas of Differentially Interacting Hallmarks of Cancer Proteins
Kori, M., Ozdemir, G. E., Arğa, K. Y., & Sinha, R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111919 · Cited by 6
Jiang, F., Shi, Y., Wang, Y., Ge, C., Zhu, J., Fang, H., Zhang, Y. X., Zhang, Y., Jian, H., Lei, T., et al. (2023) · Aging · doi:10.18632/aging.204591 · Cited by 6
MKRN1/2 serve as tumor suppressors in renal clear cell carcinoma by regulating the expression of p53
Yang, Y., Luo, Y., Huang, S., Tao, Y., Li, C., & Wang, C. (2023) · Cancer Biomarkers · doi:10.3233/cbm-210559 · Cited by 7
IFIT2 Depletion Promotes Cancer Stem Cell-like Phenotypes in Oral Cancer
Lai, K., Regmi, P., Liu, C., Lo, J., & Lee, T. (2023) · Biomedicines · doi:10.3390/biomedicines11030896 · Cited by 6
Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer
Ware, A. P., Satyamoorthy, K., & Paul, B. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01191-0 · Cited by 7
Pernar, M., Tadić, V., Kralj, J., Periša, M. M., Orešković, S., Babić, I., Banović, V., Zhang, W., Čulig, Z., & Brozović, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115349 · Cited by 6
Zhang, L., Yu, S., Hong, S., Xiao, X. O., Liao, Z., Li, Y., & Xiao, H. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01676-8 · Cited by 6
Zeng, Y., Gao, F., Zhang, C. M., Ren, P.-P., Ma, L., Wang, X., Wang, R., Kang, Y., & Li, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.14119 · Cited by 6
Gan, L., Yang, C., Zhao, L., Wang, S., Ye, Y., & Gao, Z. (2023) · Cancers · doi:10.3390/cancers16010128 · Cited by 6
Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3
Ling, Z., Hong, L., Wu, J., & Ling, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-53489-z · Cited by 6
Prognostic Role of Receptor Tyrosine Kinase–Like Orphan Receptors in Intestinal-Type Gastric Cancer
Nema, R., Patel, P., & Kumar, A. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.7.2125 · Cited by 6
Gargya, P., & Bálint, B. L. (2021) · Cancers · doi:10.3390/cancers13174348 · Cited by 6
Chen, Y., Jiang, L., Xia, L., Zhang, G., & Chen, L. (2022) · BMC Immunology · doi:10.1186/s12865-022-00485-5 · Cited by 6
Treacle is Upregulated in Cancer and Correlates With Poor Prognosis
Oxe, K. C., & Larsen, D. H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.918544 · Cited by 6
Super-resolution imaging reveals the role of DDR1 cluster in NSCLC proliferation
Li, B., Qi, X., Li, M., Hua, P., Fu, Y., Li, L., Wang, J., Gao, J., Zhang, G., Tong, T., et al. (2024) · Talanta · doi:10.1016/j.talanta.2024.127024 · Cited by 5
The ADAMTS2 metalloproteinase inhibits tumor growth by regulating the innate immune system
Joannes, L., Dupont, L., Stock, L., Arpigny, E., Hubert, P., Ancion, M., Luyckx, M., Abinet, J., Peng, W., Calaldo, D., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03880-1 · Cited by 5
19q13.12 KRAB zinc-finger protein ZNF383 represses p53 signaling pathway by interacting with p53
Liang, Y., Zhang, X., Geng, W., Wang, Y., Ding, Y., Song, Q., Yuan, Y., Zhao, C., Tian, Z., Wang, J., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110405 · Cited by 5
Liu, F., Wan, S., Li, Y., Ye, Z., Li, D., & Li, Z. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230316153813 · Cited by 5
Tan, L., Li, W., & Su, Q. (2023) · PeerJ · doi:10.7717/peerj.16263 · Cited by 5
Comprehensive analysis of autophagy associated genes and immune infiltrates in cervical cancer.
Li, S., Gao, K., & Yao, D. (2024) · PubMed Central · doi:10.22038/ijbms.2024.74431.16168 · Cited by 5
Sinha, S., Arora, R., Kutluberk, E., Verly, M., Small, C., Herik, A., Burnett, L., Cao, L., Manoharan, V. T., Chockalingam, K., et al. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.07.022 · Cited by 5
In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC
Gregoris, F., Minervini, G., & Tosatto, S. C. E. (2024) · Genes · doi:10.3390/genes15091167 · Cited by 5
Chen, C., Liu, S., & Ma, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40329 · Cited by 5
Wu, M.-C., Yang, S., Fang, W.-K., Chen, T.-J., Wu, C.-Y., Hsu, Y.-J., Shen, C.-E., Cheng, Y., Hsieh, W.-C., Yuh, C., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05693-x · Cited by 5
Sakuma, Y., Hirai, S., Sumi, T., Tada, M., Kojima, T., Niki, T., & Yamaguchi, M. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112763 · Cited by 5
Perturbation of BRMS1 interactome reveals pathways that impact metastasis
Zimmermann, R. C., Sardiu, M. E., Manton, C. A., Miah, S., Banks, C. A. S., Adams, M. K., Koestler, D. C., Hurst, D. R., Edmonds, M. D., Washburn, M. P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259128 · Cited by 5
Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma
Meng, X., Dong, S., Yangyang, L., Wang, S., Xu, X., Liu, T., & Zhuang, X. (2022) · Medicine · doi:10.1097/md.0000000000028869 · Cited by 5
High P2X6 receptor expression in human bladder cancer predicts good survival prognosis
Dietrich, F., Cappellari, A. R., Filippi‐Chiela, E. C., de Paula, P. B., de Souza, J. B., Agatti, S. W., Andrejew, R., Roesler, R., Morrone, F. B., & Battastini, A. M. O. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04425-0 · Cited by 5
A Signature of Three microRNAs Is a Potential Diagnostic Biomarker for Glioblastoma
Yazdi, A. H., Zarrinpour, V., Moslemi, E., & Forghanifard, M. M. (2022) · Iranian Biomedical Journal · doi:10.52547/ibj.3671 · Cited by 5
Exploring the oncogenic roles of LINC00857 in pan-cancer
Ren, X., Liu, J., Wang, R., Liu, X., Ma, X., Lü, Z., Hu, Z., Zheng, M., Ma, J., & Li, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.996686 · Cited by 5
Identifying key mutations of radioresponsive genes in esophageal squamous cell carcinoma
Xu, X., Wang, Y., Bai, Y., Lü, J., Guo, Y., Wang, X., Rong, L., Tang, J., Ma, X., Ma, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001173 · Cited by 5
Lu, Z., Chen, Y., Chen, S., Zhu, X., Wang, C., Wang, Z., & Yao, Q. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1494520 · Cited by 5
Angajala, A., Raymond, H., Muhammad, A. I., Ahmed, M. S. U., Haleema, S., Haque, M., Wang, H., Campbell, M. J., Martini, R. N., Karanam, B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-26000-9 · Cited by 5
Multi-angle Support Vector Survival Analysis with Neural Tangent Kernel Study
Zhai, Y., Zhang, Y., Liu, H., & Zhang, Z. (2023) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-022-07540-8 · Cited by 5
de Amorim, Í. S. S., Dias, I. X., Pinheiro, D., de Carvalho, S. N., Nicolau‐Neto, P., Rodrigues, J. A., Siqueira, P. B., Oliveira, M. D. S., Panis, C., da Fonseca, A. D. S., et al. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2022.12.007 · Cited by 5
Liu, Q., Liu, Y., Chen, X., Tao, B.-Y., Chen, K., Li, W., Xu, C.-T., Shi, Y. K., Li, H., & Liu, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1071722 · Cited by 5
Hung, J. S.-C., Perez, S. M., Dasa, S. S. K., Hall, S. P., Heckert, D. B., Murphy, B. P., Crawford, H. C., Kelly, K. A., & Brinton, L. T. (2023) · Pharmaceuticals · doi:10.3390/ph16030389 · Cited by 6
Zaki, M. S. A., Eldeen, M. A., Abdulsahib, W. K., Shati, A. A., Alqahtani, Y. A., Al‐Qahtani, S. M., Otifi, H. M., Asiri, A., Hassan, H. M., Ahmed, H. E. M., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13091613 · Cited by 6
MiR-183-5p promotes renal cell carcinoma metastasis by targeting TET1
Jin, S.-N., Chen, L., Wu, J., Chen, M., Wang, H., Hu, H., Yu, L., & Zeng, S. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231184997 · Cited by 5
Identifying Cancer Type-Specific Transcriptional Programs through Network Analysis
Kurup, J. T., Kim, S., & Kidder, B. L. (2023) · Cancers · doi:10.3390/cancers15164167 · Cited by 5
Zhang, C., Xie, L., & Lin, Z. (2023) · Cell Biology International · doi:10.1002/cbin.12087 · Cited by 5
Neophytou, C. M., Katsonouri, A., Christodoulou, M., & Papageorgis, P. (2023) · Toxics · doi:10.3390/toxics11100856 · Cited by 5
Cadherin dysregulation in gastric cancer: insights into gene expression, pathways, and prognosis
Wang, H., Mazzocca, A., & Gao, P. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-700 · Cited by 5
Buva, K. B., Kumbhar, G. M., Deshmukh, A., & Ladke, V. S. (2024) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2023-0262 · Cited by 5
In silico analysis of overall survival with YBX1 in male and female solid tumours
Grimes, D. R., Rassamegevanon, T., & Marignol, L. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-57771-y · Cited by 5
Feng, Z., Yuan, L., Ma, L., Yu, W., Kheir, F. M., Käsmann, L., Brueckl, W. M., Jin, K., Wang, D., Shen, Y., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-344 · Cited by 5
Chen, Y., Zou, Q., Chen, Q., Wang, S., Du, Q., Mai, Q., Wang, X., Lin, X., Du, L., Yao, S., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36240 · Cited by 5
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer
Li, J., Yang, H., Qi, Y., Yu, P., Han, X., Zhang, Z., Zhao, K., Yin, X., Zhu, G., Yan, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74247-1 · Cited by 5
Zhang, L., Wang, S., & Wang, L. (2024) · BMC Cancer · doi:10.1186/s12885-024-13257-8 · Cited by 5
BARD1 is an ATPase activating protein for OLA1
Chen, T., Yeh, H., Chen, P.-P., Huang, W.-T., Wu, C.-Y., Liao, T.-C., Lin, S.-L., Chen, Y.-Y., Lin, K., Hsu, S. D., et al. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130099 · Cited by 5
Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors
Ershov, P. V., Yablokov, E. O., Kaluzhskiy, L. A., Mezentsev, Y. V., & Ivanov, A. S. (2022) · Biology · doi:10.3390/biology11040590 · Cited by 6
In Vitro Insertional Mutagenesis Screen Identifies Novel Genes Driving Breast Cancer Metastasis
Miskey, C., Botezatu, L., Temiz, N. A., Gogol‐Döring, A., Bartha, Á., Győrffy, B., Largaespada, D. A., Ivics, Z., & Sebe, A. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0772 · Cited by 6
Self-citationTreeck, O., Weber, F., Fritsch, J. H., Skrzypczak, M., Schüler‐Toprak, S., Buechler, C., & Ortmann, O. (2022) · Biomedicines · doi:10.3390/biomedicines10071727 · Cited by 5
Mameri, H., Buhagiar‐Labarchède, G., Fontaine, G., Corcelle, C., Barette, C., Onclercq, R., Beauvineau, C., Mahuteau‐Betzer, F., & Amor-Guéret, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04487-9 · Cited by 5
Chen, Z., Wu, R., Ma, J., & Zheng, J. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-424 · Cited by 5
Wong, R., Patel, R., Mejía, N. A. C., Guerra-Londoño, J. J., Huang, H., Gundre, S., Napa, N., & Cata, J. P. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.02.042 · Cited by 4
Recalde‐Percaz, L., la Guia-Lopez, I. D., Linzoain-Agos, P., Noguera‐Castells, A., Rodrigo‐Faus, M., Jauregui, P., López‐Plana, A., Fernández‐Nogueira, P., Iniesta‐González, M., Cueto‐Remacha, M., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101220 · Cited by 7
Li, L., Zhang, Y.-H., Wang, H., & Wang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-15196-4 · Cited by 4
Wu, D., He, L., Xu, Z., Tian, R.-F., Fan, X., Fan, J., Ai, J., Bian, H., Qin, W., Qin, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1168462 · Cited by 4
Gao, Y., Chen, Y., Liu, M., Zeng, D.-B., Tan, F., Wan, H., Liu, X., Su, S., Zhang, Y., Zhang, Y., et al. (2023) · PubMed Central · Cited by 4
Zhou, X., Li, Y., Pan, M., Lu, T., Liu, C., Wang, Z., Tang, F., & Hu, G. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01474-5 · Cited by 4
Παπαδάκος, Κ. Σ., Gorji‐Bahri, G., Gialeli, C., Hedner, C., Hagerling, C., Svensson, M. C., Jeremiasen, M., Borg, D., Fristedt, R., Jirström, K., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03656-y · Cited by 4
Fang, Z., Bunston, C., Xu, Y., Ruge, F., Sui, L., Liu, M., Al-Sarireh, B., Griffiths, P., Murphy, K., Pugh, M., et al. (2024) · Cancers · doi:10.3390/cancers16162893 · Cited by 4
Pan-Cancer Insights: A Study of Microbial Metabolite Receptors in Malignancy Dynamics
Dovrolis, N., Spathakis, M., Collins, A. R., Pandey, V. K., Uddin, M. I., Anderson, D. D., Kaminska, T., Paspaliaris, V., & Kolios, G. C. (2024) · Cancers · doi:10.3390/cancers16244178 · Cited by 4
Yang, Y., Ma, Y., Yuan, M., Peng, Y., Fang, Z., & Wang, J. (2021) · Liver International · doi:10.1111/liv.14972 · Cited by 4
Effect of F11R Gene Knockdown on Malignant Biological Behaviors of Pancreatic Cancer Cells
Zhang, H., Zhang, R., Yao, J., Hu, X., Pu, Y., He, S., Yu, J., Zhu, H., Mu, B., & Zhao, C. (2022) · Journal of Oncology · doi:10.1155/2022/3379027 · Cited by 5
LIM1 contributes to the malignant potential of endometrial cancer
Kato, H., Saeki, N., Imai, M., Onji, H., Yano, A., Yoshida, S., Sakaue, T., Fujioka, T., Sugiyama, T., & Imai, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1082441 · Cited by 4
Xiang, J., Wu, X., Liu, W., Wei, H., Zhu, Z., Liu, S., Song, C., Gu, Q., Wei, S., & Zhang, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16152 · Cited by 4
RetractedKido, A., Ishikawa, A., Fukui, T., Katsuya, N., Kuraoka, K., Sentani, K., Tazuma, S., Sudo, T., Serikawa, M., Oka, S., et al. (2023) · Pathobiology · doi:10.1159/000535542 · Cited by 4
Bhatia, A., Upadhyay, A. K., & Sharma, S. (2024) · Pharmacogenomics · doi:10.1080/14622416.2024.2355864 · Cited by 4
Eid, R. A., Mamdouh, F., Abdulsahib, W. K., Alshaya, D. S., Al‐Salmi, F. A., Alghamdi, M. A., Jafri, I., Fayad, E., Alsharif, G., Zaki, M. S. A., et al. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1387919 · Cited by 4
Metadata
- Authors
- Nagy, Á., Munkácsy, G., & Győrffy, B.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Győrffy, Balázs
- Venue
- Scientific Reports
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 1
- Pages
- 6047-6047
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7961001
- OpenAlex
- W3139511935
- Cited by
- 1,381
- References
- 40
- Citations by year
- 2026: 38 · 2025: 84 · 2024: 145 · 2023: 504 · 2022: 311 · 2021: 298
- FWCI
- 101.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Semmelweis Egyetem
- Innovációs és Technológiai Minisztérium (ÚNKP-19-3, 2018-2.1.17-TET-KR-00001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- prognostic gene signature, survival analysis, genomic instability, invasion and metastasis, replicative immortality, cell death resistance, angiogenesis, tumor suppressor, BRCA1, RUNX1, SERPINE1, CDK1, E2F1, epiregulin, c-Myc, clear cell renal cell carcinoma, low-grade glioma, cervical cancer, bladder cancer, thyroid cancer, glioblastoma, tissue specificity, targeted therapy
- MeSH terms
- RNA-Seq, Humans, Neoplasms, Biomarkers, Tumor, Survival Rate, Disease-Free Survival, Databases, Nucleic Acid, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
